Results 1 to 10 of about 1,472 (172)

Case Report: Omadacycline in the Treatment of Community‐Acquired Pneumonia in a Child With Multiple Antimicrobial Allergies [PDF]

Clinical Case Reports
Omadacycline, a novel once‐daily aminomethylcycline antibiotic agent, demonstrates efficacy against prevalent pathogens responsible for community‐acquired pneumonia (CAP) in adults.
Ziqi Xu, Wen Pan, Hui Lei, Chen Dong, Biao Zou, Sainan Shu, Wenting Zhang   +6 more
doaj   +3 more sources

Efficacy of drug regimens containing omadacycline in a murine model of Mycobacterium avium chronic lung infection [PDF]

Frontiers in Microbiology
Mycobacterium avium complex (MAC) is the most common non-tuberculous mycobacteria (NTM) and most frequent causative pathogen of NTM pulmonary infections. MAC is often associated with comorbidities, chronic infections, and high mortality rates.
Jean-Philippe Lanoix, Jean-Philippe Lanoix, Antoine Froment, Antoine Froment, Julia Delomez, Julia Delomez, Jessica V. Pierce, Alisa W. Serio, Morgane Choquet, Marie Perret, François Peltier, Cédric Joseph, Denis Chatelain, Claire Andréjak, Claire Andréjak   +14 more
doaj   +2 more sources

Omadacycline versus moxifloxacin for community-acquired bacterial pneumonia (OPTIC-2): a phase 3b, randomised, double-blind, multicentre, controlled, noninferiority trialResearch in context [PDF]

EClinicalMedicine
Summary: Background: Omadacycline is a first-in-class aminomethylcycline antibiotic approved to treat adults with community-acquired bacterial pneumonia (CABP).
Thomas M. File, Jr., Keith S. Kaye, Skliarov Ihor, Iryna Hovbakh, Vakhtang Katsarava, Courtney Kirsch, Karan Soni, Kushagra Gupta, Amy Manley, Daniel H. Deck, Diane Anastasiou, Surya Chitra, Stephen Villano   +12 more
doaj   +2 more sources

In vitro and in vivo activity of omadacycline against Mycobacterium tuberculosis [PDF]

Frontiers in Microbiology
The bedaquiline (B), pretomanid (Pa), and linezolid (L) (BPaL) regimen is highly effective for drug-resistant tuberculosis (TB) but is limited by linezolid-associated toxicities, including myelosuppression and peripheral neuropathy.
Shahebraj Khan, Duc Nguyen, Dejan Nikolic, Baojie Wan, Akil Hossain, Mallique Qader, Sanghyun Cho, Scott G. Franzblau, Gauri S. Shetye   +8 more
doaj   +2 more sources

Omadacycline Pharmacokinetics: Characteristics, Contributing Factors, and Clinical Significance [PDF]

Drugs in R&D
Omadacycline is a novel tetracycline with a wide range of antibacterial activity. A comprehensive understanding of the factors influencing its metabolic processes is essential to optimize its therapeutic benefits and minimize any potential negative ...
Huan Sun, Xiaoli Hou, Qiuzhen Zhu, Juan Liu, Qiaoli Zhai, Kourong Shi   +5 more
doaj   +2 more sources

Surveillance of omadacycline activity tested against clinical isolates from the USA: report from the SENTRY Antimicrobial Surveillance Program, 2019

Journal of Global Antimicrobial Resistance, 2021
: Objectives: Omadacycline was tested against 7000 bacterial isolates collected prospectively from medical centres in the USA during 2019. Methods: Antimicrobial susceptibility testing was performed according to Clinical and Laboratory Standards ...
Michael D Huband, Dee Shortridge, Robert K Flamm   +2 more
exaly   +3 more sources

Omadacycline for the treatment of acute bacterial skin and skin structure infections: a systematic review and network meta-analysis [PDF]

BMC Infectious Diseases
Background Few studies have compared the efficacy and safety of omadacycline with other treatments for acute bacterial skin and skin structure infections (ABSSSI). Therefore, updated meta-analyses on this topic is necessary.
Wen-qiang Kong, Yun-feng Shu , Juan Tang, Shi-qin Li, Hong Zhong, Xuan-yi Zhang   +5 more
doaj   +2 more sources

Multicenter Real-World Outpatient Use of Intravenous Omadacycline [PDF]

Infectious Diseases and Therapy
Introduction Omadacycline is indicated for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia.
Lucinda J. Van Anglen, Cathy L. Koo, Kimberly A. Couch   +2 more
doaj   +2 more sources

Efficacy and safety of omadacycline for the treatment of infectious diseases: a real-world, retrospective study of 2587 patients [PDF]

Frontiers in Pharmacology
ObjectivePrevious randomized controlled trials have shown good efficacy and safety of omadacycline in patients with infectious diseases, but relevant real-world evidence is still insufficient.
Jian Liu, Jiayi Liu, Jiayi Liu, Huangyi Li, Jiali Pang, Siyun Chen, Jianming Liu, Aijun Ouyang   +7 more
doaj   +2 more sources

Omadacycline for Acute Bacterial Skin and Skin Structure Infections

Clinical Infectious Diseases, 2019
Acute bacterial skin and skin-structure infections are associated with substantial morbidity and health care costs. Omadacycline, an aminomethylcycline antibiotic that can be administered once daily either orally or intravenously, is active against pathogens that commonly cause such infections, including antibiotic-resistant strains.In this double ...
Fredrick M Abrahamian, George Sakoulas, Evan Tzanis   +2 more
exaly   +4 more sources